MKKGY
Merck KGaA
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Buy
+37/100
Last price
31.25
▲ 0.56 (1.82%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
30.69
Day high
31.66
Day low
31.14
Volume
12.25K
Market cap
$67.93B
P/E (TTM)
24.61
52W range
23.73 – 34.19
Trailing performance
Returnvs SPY
1W
-0.19%
-2.1%
1M
-0.83%
-2.0%
3M
-2.28%
-6.8%
6M
+24.06%
+5.9%
YTD
+8.96%
-5.3%
1Y
+9.96%
-6.5%
3Y
-6.30%
-88.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on MKKGY open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Fundamentals
Market cap$67.93B
Enterprise value$77.04B
Revenue (TTM)$21.13B
Gross profit$12.49B
EBITDA$5.59B
Net income$2.37B
EPS (TTM)$1.27
Free cash flow$2.63B
Total cash$3.12B
Total debt$12.30B
Book value / share$15.61
Shares outstanding646.21M
Float644.35M
Short % of float—
Dividend yield1.65%
Beta (5Y)0.79
Valuation & profitability ratios
Trailing P/E24.61
Forward P/E15.39
PEG ratio2.20
Price / sales—
Price / book2.00
EV / revenue3.65
EV / EBITDA13.79
Gross margin59.09%
Operating margin13.86%
Profit margin11.21%
Return on equity8.13%
Return on assets4.65%
Debt / equity40.62
Current ratio1.70
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $21.10B | $21.16B | $20.99B | $22.23B | -0.3% |
| Operating revenue | $21.10B | $21.16B | $20.99B | $22.23B | -0.3% |
| Cost of revenue | $8.76B | $8.67B | $8.60B | $8.53B | +1.0% |
| Gross profit | $12.35B | $12.48B | $12.39B | $13.71B | -1.1% |
| Research & development | $2.42B | $2.28B | $2.44B | $2.52B | +6.0% |
| Selling, general & admin | $5.49B | $5.36B | $5.33B | $5.41B | +2.5% |
| Total operating expense | $8.69B | $8.48B | $8.82B | $8.95B | +2.5% |
| Operating income | $3.66B | $4.01B | $3.57B | $4.75B | -8.8% |
| Net interest income | -$284.00M | -$139.00M | -$151.00M | -$157.00M | -104.3% |
| Pre-tax income | $3.31B | $3.54B | $3.48B | $4.29B | -6.4% |
| Tax provision | $693.00M | $751.00M | $650.00M | $948.00M | -7.7% |
| Net income | $2.61B | $2.78B | $2.82B | $3.33B | -6.1% |
| Net income to common | $2.61B | $2.78B | $2.82B | $3.33B | -6.1% |
| Basic EPS | 1.20 | 1.28 | 1.30 | 1.53 | -6.1% |
| Diluted EPS | 1.20 | 1.28 | 1.30 | 1.53 | -6.1% |
| EBIT | $3.69B | $3.83B | $3.81B | $4.52B | -3.5% |
| EBITDA | $5.99B | $5.96B | $5.68B | $6.55B | +0.5% |
| Basic shares | 2.17B | 2.17B | 2.17B | 2.17B | 0.0% |
| Diluted shares | 2.17B | 2.17B | 2.17B | 2.17B | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $2.33B | $2.15B | $1.58B | $1.40B | +8.3% |
| Cash & short-term investments | $2.92B | $2.71B | $2.01B | $1.64B | +8.0% |
| Accounts receivable | $3.95B | $3.95B | $4.00B | $4.11B | 0.0% |
| Inventory | $4.56B | $4.48B | $4.64B | $4.63B | +1.7% |
| Total current assets | $13.23B | $13.45B | $12.39B | $12.20B | -1.6% |
| Property, plant & equipment | $9.94B | $10.03B | $9.06B | $8.20B | -0.8% |
| Goodwill & intangibles | $25.59B | $25.46B | $24.40B | $25.72B | +0.5% |
| Total assets | $51.53B | $51.60B | $48.49B | $48.53B | -0.1% |
| Total current liabilities | $9.04B | $11.29B | $8.70B | $9.51B | -19.9% |
| Current debt | $1.10B | $3.14B | $503.00M | $1.07B | -65.0% |
| Long-term debt | $10.21B | $6.37B | $8.85B | $8.83B | +60.1% |
| Total debt | $11.95B | $10.27B | $9.86B | $10.40B | +16.4% |
| Total liabilities | $22.87B | $21.61B | $21.74B | $22.53B | +5.8% |
| Retained earnings | $24.04B | $22.09B | $20.23B | $18.46B | +8.8% |
| Shareholder equity | $28.59B | $29.91B | $26.68B | $25.93B | -4.4% |
| Working capital | $4.19B | $2.15B | $3.69B | $2.69B | +94.3% |
| Net tangible assets | $3.00B | $4.46B | $2.28B | $204.00M | -32.7% |
| Shares issued | 434.78M | 434.78M | 434.78M | 434.78M | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $2.62B | $2.79B | $2.83B | $3.34B | -6.1% |
| Depreciation & amortisation | $2.30B | $2.13B | $1.88B | $2.03B | +7.7% |
| Change in working capital | -$814.00M | -$310.00M | -$707.00M | -$1.08B | -162.6% |
| Operating cash flow | $3.93B | $4.59B | $3.78B | $4.26B | -14.3% |
| Capital expenditure | -$1.96B | -$2.18B | -$2.02B | -$1.81B | +10.3% |
| Investing cash flow | -$4.26B | -$3.05B | -$1.89B | -$2.74B | -39.7% |
| Dividends paid | -$284.00M | -$284.00M | -$284.00M | -$239.00M | 0.0% |
| Financing cash flow | $628.00M | -$985.00M | -$1.73B | -$1.55B | +163.8% |
| Free cash flow | $1.97B | $2.40B | $1.76B | $2.45B | -17.8% |
| End cash position | $2.74B | $2.52B | $1.98B | $1.85B | +8.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | — | $5.13B | $5.25B | $5.32B | $5.25B | $5.28B | — |
| Operating revenue | — | $5.13B | $5.25B | $5.32B | $5.25B | $5.28B | — |
| Cost of revenue | — | $2.07B | $2.29B | $2.10B | $2.23B | $2.13B | — |
| Gross profit | — | $3.06B | $2.96B | $3.21B | $3.03B | $3.15B | — |
| Research & development | — | $658.00M | $664.00M | $660.00M | $539.00M | $551.00M | — |
| Selling, general & admin | — | $1.52B | $1.09B | $1.46B | $1.48B | $1.47B | — |
| Total operating expense | — | $2.12B | $2.41B | $2.00B | $2.13B | $2.14B | — |
| Operating income | — | $943.00M | $547.00M | $1.21B | $892.00M | $1.01B | — |
| Net interest income | — | -$68.00M | -$73.00M | -$99.00M | -$62.00M | -$50.00M | — |
| Pre-tax income | — | $869.00M | $401.00M | $1.12B | $829.00M | $956.00M | — |
| Tax provision | — | $200.00M | $77.00M | $225.00M | $174.00M | $218.00M | — |
| Net income | — | $659.00M | $319.00M | $902.00M | $652.00M | $735.00M | — |
| Net income to common | — | $659.00M | $319.00M | $902.00M | $652.00M | $735.00M | — |
| Basic EPS | 0.23 | 0.30 | — | 0.41 | 0.30 | 0.34 | -25.7% |
| Diluted EPS | 0.23 | 0.30 | — | 0.41 | 0.30 | 0.34 | -25.7% |
| EBIT | — | $973.00M | $504.00M | $1.25B | $908.00M | $1.03B | — |
| EBITDA | — | $1.47B | $1.41B | $1.71B | $1.36B | $1.51B | — |
| Basic shares | 2.19B | 2.17B | — | 2.18B | 2.17B | 2.17B | +0.8% |
| Diluted shares | 2.19B | 2.17B | — | 2.18B | 2.17B | 2.17B | +0.8% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.74B | $2.33B | $2.25B | $1.17B | $1.00B | +17.8% |
| Cash & short-term investments | $3.77B | $2.92B | $2.92B | $1.57B | $1.62B | +29.0% |
| Accounts receivable | $4.32B | $3.95B | $4.22B | $4.23B | $4.34B | +9.4% |
| Inventory | $4.78B | $4.56B | $4.51B | $4.47B | $4.51B | +4.8% |
| Total current assets | $14.16B | $13.23B | $12.88B | $12.20B | $12.41B | +7.0% |
| Property, plant & equipment | $10.04B | $9.94B | $9.78B | $9.66B | $9.85B | +1.0% |
| Goodwill & intangibles | $26.05B | $25.59B | $25.63B | $22.93B | $24.56B | +1.8% |
| Total assets | $53.07B | $51.53B | $50.93B | $47.35B | $49.37B | +3.0% |
| Total current liabilities | $9.35B | $9.04B | $8.64B | $9.86B | $9.50B | +3.4% |
| Current debt | — | $1.10B | — | — | — | — |
| Long-term debt | — | $10.21B | — | — | — | — |
| Total debt | $12.04B | $11.95B | $12.10B | $9.40B | $8.70B | +0.7% |
| Total liabilities | $23.25B | $22.87B | $21.93B | $19.02B | $19.48B | +1.7% |
| Retained earnings | $24.69B | $24.04B | $24.20B | $23.34B | $22.98B | +2.7% |
| Shareholder equity | $29.74B | $28.59B | $28.94B | $28.26B | $29.82B | +4.0% |
| Working capital | $4.81B | $4.19B | $4.24B | $2.34B | $2.91B | +14.9% |
| Net tangible assets | $3.70B | $3.00B | $3.30B | $5.33B | $5.27B | +23.3% |
| Shares issued | 434.78M | 434.78M | 434.78M | 434.78M | 434.78M | 0.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | $669.00M | $324.00M | $898.00M | $655.00M | $738.00M | +106.5% |
| Depreciation & amortisation | $497.00M | $910.00M | $458.00M | $457.00M | $473.00M | -45.4% |
| Change in working capital | -$309.00M | $62.00M | $332.00M | -$543.00M | -$666.00M | -598.4% |
| Operating cash flow | $818.00M | $1.29B | $1.52B | $567.00M | $556.00M | -36.6% |
| Capital expenditure | -$546.00M | -$528.00M | -$461.00M | -$444.00M | -$524.00M | -3.4% |
| Investing cash flow | -$755.00M | -$583.00M | -$3.12B | -$143.00M | -$419.00M | -29.5% |
| Dividends paid | -$14.00M | $0 | — | -$284.00M | -$46.00M | — |
| Financing cash flow | -$62.00M | -$210.00M | $2.70B | -$257.00M | -$1.61B | +70.5% |
| Free cash flow | $272.00M | $763.00M | $1.06B | $123.00M | $32.00M | -64.4% |
| End cash position | $2.74B | $2.74B | $2.25B | $1.17B | $1.00B | +0.1% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.47 | 0.50 | +5.9% |
| Mar 2026 | 0.47 | 0.49 | +4.5% |
| Dec 2025 | 0.49 | 0.43 | -11.7% |
| Sep 2025 | 0.54 | 0.54 | -1.1% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.47 | 1 | $5.37B | +0.9% |
| Next quarter | 0.49 | 1 | $5.40B | +2.8% |
| Current year | 1.95 | 1 | $21.48B | +1.8% |
| Next year | 2.03 | 1 | $22.64B | +5.4% |
Analyst targets & ownership
Mean target$36.03
High target$36.40
Low target$35.65
Implied upside15.28%
Analyst count2
ConsensusSTRONG BUY
Strong buy / Buy1 / 1
Hold0
Sell / Strong sell0 / 0
Held by insiders0.00%
Held by institutions0.02%
Institutions holding8
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
30.87
+1.25% from price
SMA 20
30.58
+2.19% from price
SMA 50
31.75
-1.58% from price
SMA 100
31.46
-0.67% from price
SMA 200
29.60
+5.57% from price
EMA 12
30.84
+1.33% from price
EMA 26
31.01
+0.77% from price
EMA 50
31.22
+0.09% from price
RSI (14)
52.2
Neutral
MACD (12,26,9)
-0.17
Hist 0.11
ATR (14)
0.64
2.05% of price
Realised vol 30D
20.6%
Annualised
Bollinger upper
31.55
20, 2σ
Bollinger lower
29.61
20, 2σ
50 / 200 cross
Golden
31.75 vs 29.60
Trend bias
Above 200
+5.57%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.94
Less volatile than market
Correlation to SPY
0.42
Loosely linked
Realised vol 30D
20.6%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-22.9%
Peak to trough
Max drawdown 5Y
-54.3%
Peak to trough
ATR 14
0.64
2.05% of price
Beta (reported)
0.79
5Y monthly, from filing
Dividends & splits
Forward rate$0.51 / yr
Forward yield1.65%
5-year avg yield1.30%
Payout ratio40.60%
Ex-dividend dateApr 28, 2026
Next pay dateMay 6, 2026
Last split1666:1000
Split dateAug 15, 2017
Headlines
EMD Electronics opens semiconductor R&D hub in Wisconsin
Verdict · 2d ago
3 European Defensive Stocks Investors Are Watching As Bond Markets Turn Risk Off
Simply Wall St. · 4d ago
EMD Electronics Opens New R&D Facility in Wisconsin to Accelerate Advanced Semiconductor Materials Innovation
GlobeNewswire · 5d ago
Cell and Gene Therapy Bio-Manufacturing Market Global Report 2026: Market to Surge to $21.46 Billion by 2030 as Thermo Fisher Scientific, Merck KGaA, Lonza and Samsung Biologics Accelerate Automation
GlobeNewswire · 6d ago
Biomarkers Market Forecasts Growth from $67.95B (2026) to $112.10B by 2031, Profiling Roche, Abbott, Thermo Fisher & Qiagen
GlobeNewswire · 6d ago
Recombinant Proteins Market - Global Strategic Business Report: Sales Hit to $5.8 Billion by 2030 - Benchmark Thermo Fisher Scientific, Merck KGaA, Amgen, Bio-Techne and GenScript Biotech Amid Tariff Disruption
GlobeNewswire · 7d ago
Fetal Bovine Serum Market Outlook 2026-2035 - Featuring Profiles of Leading Companies Thermo Fisher Scientific, Merck KGaA, and Cytiva
GlobeNewswire · 7d ago
Photoactive Materials Market - Global Strategic Business Report: Capitalize on the $1.2 Billion 2030 Revenue Shift as Organic Materials Hit $873 Million and BASF, DuPont, Merck KGaA and Oxford Photovoltaics Race to Dominate
GlobeNewswire · 9d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.